United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$331.04 USD
+8.81 (2.73%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $330.84 -0.20 (-0.06%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth F Momentum D VGM
Brokerage Reports
0 items in cart
United Therapeutics Corporation [UTHR]
Reports for Purchase
Showing records 341 - 360 ( 601 total )
Company: United Therapeutics Corporation
Industry: Medical - Drugs
UTHR Continues Uphill Battle Against IPR Following Oral Hearing
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
2016 World Orphan Drug Congress Recap: Emerging Trends in Rare Disease Therapeutics
Provider: Rodman & Renshaw, Co.
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
November and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q3 Review: Top and Bottom Line Beat; Pipeline Expansion Points to Expanding Revenue Potential; Reiterate OUTPERFORM and $229 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q3 Preview: Consensus Revenues Appear Achievable In Our View; Reiterate OUTPERFORM and $229
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Litigation Timetable and In-depth Look at Tyvaso IP
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
October and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
September and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
August and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Competitive Pressures Materialize; Expect Increased Clarity on Additional Attacks in Coming Quarters
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q2 Financials Strong Beat and Long-Term Growth from New Products and Expansion into New Indications; Reiterate OUTPERFORM and $229 PT.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
The Week Ahead in Life Sciences: Upcoming Events for the Week of July 25
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q2 Preview: We Believe Consensus Is Achievable;Reiterate OUTPERFORM and $229 Price Target.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q2 Preview: We Project Top- and Bottom-line Beat on Solid Product Sales; Reiterate OUTPERFORM and $229 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L